None of the 10 largest U.S. drugmakers have lowered prescription drug prices as a result of the tax reform passed in 2017, according to an analysis from the office of Sen. Cory Booker (D-N.J.).
Source: Drug Industry Daily
None of the 10 largest U.S. drugmakers have lowered prescription drug prices as a result of the tax reform passed in 2017, according to an analysis from the office of Sen. Cory Booker (D-N.J.).
Source: Drug Industry Daily